What they say:
A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published, in the 7 March 2013 issue of of the journal Nature, by Prof Dimmler, Boon, and others.
What we say:
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Protect your heart from Myocardial dysfunction and cardiac ageing with Influenza vaccine : Influenza A (H1N1) vaccine induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction, via up regulation of PNUTS
From Significance of the study to Public Health relevance:
Given that: (1) cardiovascular disease is the leading cause of death worldwide; (2) the raise of death rate, due to cardiovascular disease, has increased from 123 lakhs in 1990 to 173 lakhs in 2013; (3) 85% of people over 80 years are susceptible to cardiovascular diseases;(4) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; (3) the death due to cardiovascular disease is higher in low-to-middle income countries compared to developed countries; (4) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars; (5) an alarming number of people, such as 230 lakhs people, will die from cardiovascular diseases each year by 2030, there is an urgent need to find: (i) a way to induce regeneration of cardiomyocytes that were lost in Myocardial patients; (ii) a cheaper alternative to the existing expensive drugs; and (iv) a side-effect-free Natural product-based drug.
From Research Findings to Therapeutic Opportunity:
This study suggests, for the first time, an Influenza A (H1N1) vaccine (flu vaccine)-based therapy, with detailed mechanistic insights, for protecting myocardium following acute myocardial infarction. There is a scant evidence that suggests Influenza A (H1N1) vaccine may aid in the treatment of or protection against cardiovascular disease. However, the mechanism of action remains largely unknown.
Influenza A (H1N1) vaccine, by increasing the expression of its target genes, it may increase the expression of PNUTS (fig.1) . Thereby, it may: (1) inhibit DNA damage responses, (2) increase telomerase expression, (3) inhibit telomere shortening; (4) promote cardiomyocyte survival/regeneration; (5) decelerate ageing; and (6) extend life span (fig 1).
Thus, by vaccinating cardiac patients or aged ones, who may be prone to myocardial dysfunction, with Influenza A (H1N1) vaccine, one may prevent decline in cardiac function. Together, this study suggests, for the first time, that Influenza A (H1N1) vaccine, either alone or in combination with other drugs,” may be used to improve cardiac function after acute myocardial infarction (fig. 2).
Details of the research findings:
Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Undisclosed mechanistic information: How does Influenza A (H1N1) vaccine increase the expression of PNUTS/Telomerase
# Research cooperation
For purchase and payment details, you may reach us at firstname.lastname@example.org
Citation: Boominathan, L., Protect your heart from Myocardial dysfunction and cardiac ageing with Influenza vaccine : Influenza A (H1N1) vaccine induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction, via up regulation of PNUTS, 5/July/2018, 7.08 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at email@example.com